Credit rating agency, ICRA has assigned BB+ rating to enhanced Rs 149.0 crore Fund based limits (enhanced from Rs 70.0 crore), Rs 197.1 crore Term loans (enhanced from Rs 144.6 crore) and $32 million term loans (enhanced from $25.5 million) of Hikal. The outlook on the long term rating is stable. The rating agency has also assigned A4+ rating to the enhanced Rs 105 crore (earlier Rs 125 crores) fund based limits and Rs 55 crore (enhanced from Rs. 45 crore) non fund based limits of the company.
Though a part of the long term loans of the company is denominated in foreign currency, ICRA’s ratings for the same are on national rating scale, as distinct from an international rating scale.
The rating derives strength from the company’s strong product profile, entrenched relationship with leading Pharma and Agro chemicals companies in the world and strong market position for Gabapentin business.
Hikal provides world-class Active Ingredients, Intermediates and R&D services and solutions in a safe, secure and confidential manner.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |